Activating cells within the body to restore or repair the underlying causes of degenerative disease
We are a clinical-stage biotechnology company focused on restoring function by developing therapeutics that activate a person’s innate regenerative potential within the body.
Our proprietary approach, progenitor cell activation (PCA), uses small molecules to activate progenitor cells within the body to create functional tissue.
Our current therapeutic focus aims to activate existing progenitor cells in patients with multiple sclerosis to remyelinate axons and restore signal transmission. Our scientists are following early restorative signals in preclinical studies.
Our approach aims to reduce the complexity of regenerative medicine
We use small molecules to activate progenitor cells and other precursor cells where they are located, bypassing many of the challenges of cell and gene therapies.
Learn More